Rok Sekirnik completed his PhD at Oxford University. He has worked in the areas of mAb, vaccine, and gene therapy vector development. His team at Sartorius BIA Separations is focused on developing high-yielding, cost-effective purification approaches for pDNA and mRNA production.

Dan Peer, PhD, is the chairman of NeoVac as well as a professor and the director of the Laboratory of Precision NanoMedicine at Tel Aviv University. His lab was the first to show systemic, high efficiency, cell specific, therapeutic genome editing in cancer.

Heinrich Haas, PhD, has worked both in academia, where he researched lipid membranes and organized bio-molecular systems and the pharmaceutical industry (Munich Biotech, Medigene, BioNTech), where he developed nanoparticle products to clinical stage. His focus is on advanced approaches for nanoparticle development and control.

Tristan Kovacic is a Scientist in the Process Analytics Development Department at Sartorius BIA Separations and a PhD student in Computational Chemistry at the University of Maribor. He has experience in the pharmaceutical and biotech industries, focusing on process development and analytics for non-viral drug delivery systems and active pharmaceutical ingredients.

Mojca Tajnik Sbaizero, PhD, leads the Virus and Nanoparticle Innovation Group at Sartorius BIA Separations. Her prior academic work focused on pre-mRNA processing and therapeutic strategies for genetic alternative splicing diseases. At  Sartorius BIA Separations she focuses on downstream processing of viral vectors and vaccines, with recent projects emphasizing LNP process development.

Jacek Lubelski, PhD, is a biopharmaceutical leader specializing in gene and cell therapy and viral vector production, with over a decade of experience advancing rAAV therapeutics. Previously, as VP of Pharmaceutical Development at UniQure NV, he helped obtain market authorization for Glybera, the first approved gene therapy for LPL deficiency. Now, as CTO at NanoCell Therapeutics, he oversees R&D activities.